

**P36. Clinical Results Of The Medtronic Mosaic Porcine Bioprosthesis Up To 14 Years**

Friedrich-Christian Rieß; Eva Cramer; Günther Wahl; Lorenz Hansen; Ralf Bader  
*Albertinen Heart Center, Hamburg, Germany*

**OBJECTIVES:** The MOSAIC bioprosthesis is a third generation stented porcine bioprosthesis, built upon the historical durability of the HANCOCK-II bioprosthesis. The MOSAIC Aortic and Mitral bioprostheses are preserved in buffered 0.2% glutaraldehyde in a zero pressure procedure and they are treated with the AOA ( amino oleic acid) antimineralisation process, to improve hemodynamic performance and durability.

**METHODS:** The Mosaic post-approval long-term trial is prospective and non-randomized. Between 02/1994 and 10/1999 we enrolled 255 patients with AVR (mean age 67 years, range 23-82 years) and 47 patients with MVR (mean age 66,8 years, range 41-84 years) in this post-FDA trial. Patients were followed up including serial echocardiographic assessment within 30 days, six months and annual intervals thereafter. The cumulative follow-up was 1984 patient-years (pt-yrs) for AVR and 336 pt-yrs for MVR.

**RESULTS:** Early mortality after AVR{

**CONCLUSIONS:** Our midterm results demonstrate clinical safety and excellent performance of the MOSAIC bioprosthesis. Continued follow-up will determine, if this new design will provide increased durability.